Patients | Total population | |||||
---|---|---|---|---|---|---|
Correlation coeficient | Significant level (2 tailed) | n | Correlation coeficient | Significant level (2 tailed) | n | |
ABCG2 | ||||||
Creatinin (PBMCs) | 0.915 # | p < 0.001 | 18 | 0.875 # | p < 0.001 | 34 |
Uric Acid (PMNLs) | NS | NS | 18 | 0.421 § | p < 0.05 | 35 |
SLC22A12 | ||||||
MS (PBMCs) | 0.473 § | p < 0.05 | 20 | NS | NS | 34 |
UA (PBMCs) | 0.449 § | p < 0.05 | 21 | NS | NS | 35 |
TAG (PBMCs) | 0.466 # | p < 0.05 | 21 | NS | NS | 34 |
TAG (PMNLs) | 0.550§ | p < 0.05 | 15 | NS | NS | 34 |
RD (PMNLs) | 0.525 # | p < 0.05 | 16 | 0.663 § | p < 0.001 | 15 |
Hypertension (PMNLs) | 0.511 # | p < 0.05 | 16 | NS | NS | 36 |
ALPK1 | ||||||
Creatinin (PBMCs) | 0.654 § | p < 0.001 | 16 | NS | NS | 34 |
BMI (PBMCs) | NS | NS | 18 | 0.443 § | p < 0.001 | 39 |
Uric Acid (PBMCs) | 0.574 § | p < 0.05 | 16 | NS | NS | 37 |
CRP (PMNLs) | 0.620 § | p < 0.05 | 12 | NS | NS | 30 |
IL-1β | ||||||
Hypertension (PMNLs) | 0.579 § | p < 0.05 | 15 | NS | NS | 35 |